UnknownPhase 1NCT04653493
CD19 Targeted CAR T Cell Therapy in Patients With Relapsed/ Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)
Studying Acute lymphoblastic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sabz Biomedicals
- Principal Investigator
- Tahereh Rostami, M.D, MDResearch Institute for Oncology- Hematology and Cell Therapy (RIOHCT), Tehran University of Medical Sciences, Tehran, Iran
- Intervention
- CD19 CAR engineered autologous T-cells(biological)
- Enrollment
- 22 enrolled
- Eligibility
- 25 years · All sexes
- Timeline
- 2021 – 2024
Study locations (2)
- Gene therapy research center, Shariati hospital, Tehran university of medical sciences, Iran, Tehran, Iran
- Research Institute for Oncology- Hematology and Cell Therapy (RIOHCT), Tehran University of Medical Sciences, Tehran, Iran
Collaborators
Gene Therapy Research Center, Shariati Hospital, Tehran University of Medical Sciences, Iran · Research Institute for Oncology- Hematology and Cell Therapy (RIOHCT), Tehran University of Medical Sciences, Iran
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04653493 on ClinicalTrials.govOther trials for Acute lymphoblastic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT05621291A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leu...National Cancer Institute (NCI)
- RECRUITINGPHASE2NCT07328503CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT06738368Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic LeukemiaUniversity of Washington
- ENROLLING BY INVITATIONNCT07511959Autologous Exosomes From Platelet-rich Plasma as a Modern Tool of Regenerative DentistryWroclaw Medical University
- RECRUITINGNANCT07191119Transcutaneous Auricular Vagus Nerve Stimulation for Insomnia in Survivors of Childhood Acute Lymphoblastic LeukemiaSt. Jude Children's Research Hospital
- RECRUITINGNANCT07177183Low Serum Creatinine as a Predictor of Prolonged Mechanical Ventilation and Weaning FailureUniversity Hospital Ostrava
- RECRUITINGPHASE2NCT07275762Y-4 to Treat the Postherpetic NeuralgiaNeurodawn Pharmaceutical Co., Ltd.
- RECRUITINGNANCT07201974Virtual Reality for Post-Stroke Gait RehabilitationMcGill University